Gathering all analytical data from different techniques for the same sample isn’t always an easy and routine task. This problem is amplified in high-throughput environments based on sheer volume alone. Review and analysis of information can be time consuming, leading to delays in decision-making that have detrimental effects on productivity and the speed of project completion.
A new Yale Univ. study indicates that cell-to-cell transmission of HIV particles contributes to the development of full-blown AIDS and helps predict which anti-retroviral therapies will be most effective at keeping the disease at bay. The new research reinforces recent findings that a heavy concentration of the virus at the point of contact between cells is crucial to the development of AIDS.
Before doctors like Matthias Kretzler can begin using the results of molecular research to treat patients, they need science to find an effective way to match genes with the specific cells involved in disease. As Kretzler explains, finding that link would eventually let physicians create far more effective diagnostic tools and treatments.
Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction, a “cytokine storm”, that can both sicken and kill patients who are infected with certain strains of flu virus. Their findingsalso clarify the workings of a potent new class of anti-inflammatory compounds that prevent this immune overreaction in animal models.
The annual ritual of visiting a doctor’s office or health clinic to receive a flu shot may soon be outdated, thanks to the findings of a new study. The research, which involved nearly 100 people recruited in the metropolitan Atlanta area, found that test subjects could successfully apply a prototype vaccine patch to themselves.
A diverse team of scientists from Univ. of California, Los Angeles' Jonsson Comprehensive Cancer Center has developed an experimental treatment that eradicates an acute type of leukemia in mice without any detectable toxic side effects. The drug works by blocking two important metabolic pathways that the leukemia cells need to grow and spread.
Delivering drugs into the brain to treat neurological diseases and disorders has been a challenge. The current best and easiest way to get drugs anywhere in the body is to take them orally or to administer them intravenously. But the challenges for these routes of drug delivery for targets in the brain are multiple.
If a driver is traveling to New York City, I-95 might be their route of choice. But they could also take I-78, I-87 or any number of alternate routes. Most cancers begin similarly, with many possible routes to the same disease. A new study found evidence that assessing the route to cancer on a case-by-case basis might make more sense than basing a patient’s cancer treatment on commonly disrupted genes and pathways.
A light-activated drug delivery system for treating cancer is particularly promising to traditional chemotherapy methods because it can accomplish spatial and temporal control of drug release. To this end, scientists have developed a new type of nanoparticle that can absorb energy from tissue-penetrating light that releases drugs in cancer cells.
Screening more than 100 spider toxins, Yale Univ. researchers identified a protein from the venom of the Peruvian green velvet tarantula that blunts activity in pain-transmitting neurons. The findings, reported in Current Biology, show the new screening method used by the scientists has the potential to search millions of different spider toxins for safe pain-killing drugs and therapies.
Many vaccines consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky. An alternative, safer approach is a vaccine made of small fragments of proteins produced by a disease-causing virus or bacterium. This has worked for some diseases, but in many cases these vaccines don’t provoke a strong enough response. Until now.
The Food and Drug Administration on Wednesday approved a cancer drug from Pharmacyclics and Janssen Biotech Inc. for a new use against a rare blood and bone marrow disease. The agency said it approved Imbruvica for patients with chronic lymphocytic leukemia who have already tried at least one other therapy.
A majority of federal health experts said Tuesday that new research is not strong enough to conclude that naproxen, the pain reliever in Aleve and many other medications, is safer on the heart than rival drugs used by millions of Americans to treat arthritis and everyday aches and pains. The Food and Drug Administration advisory panel voted against the conclusion that naproxen has a lower risk of heart attack than ibuprofen.
Federal health experts are taking a second look this week at the heart safety of pain medications used by millions of Americans to treat arthritis and other everyday aches and pains. The Food and Drug Administration holds a two-day meeting beginning Monday to examine the latest research on anti-inflammatory medicines called NSAIDS, which serve as the backbone of U.S. pain treatment.
In 2011, biologists at Caltech demonstrated a highly effective method for delivering HIV-fighting antibodies to mice—a treatment that protected the mice from infection by a laboratory strain of HIV delivered intravenously. Now the researchers have shown that the same procedure is just as effective against a strain of HIV found in the real world, even when transmitted across mucosal surfaces.
Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this year's Winter Olympics: They're providing information on drugs that once would have been considered proprietary trade secrets. GlaxoSmithKline, Amgen and Roche are among the drugmakers that have begun sharing data about experimental drugs as part of an effort to stay one step ahead of drug cheats.
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
In the U.S. about 12,500 women are diagnosed with cervical cancer a year. Out of these women, about 4,500 progress into invasive cervical cancer or the end stage of the disease. This leaves about 8,000 women a year in the U.S. that are cured through existing standard of care treatment: surgery or chemotherapy/radiation. However, chemotherapy/radiation have terrible side effects in some cases.
As interest and investment in biopharmaceuticals grows, the pressure to innovate and rapidly deliver new therapies increases. While many avenues may be pursued, the high cost of developing biological molecules increases the need to advance only those therapies with the greatest likelihood of becoming manufacturable, efficacious, safe and profitable products.
Awareness of the benefits of gravimetric sample preparation has increased significantly over the past couple of years. Recognition of this state-of-the-art technology by industry organizations such as the United States Pharmacopeia (USP) has supported this trend. A recent revision to USP chapter 1251 “Weighing on an Analytical Balance” included a detailed description of the steps involved in gravimetric dosing for sample preparation.
The U.S. National Institutes of Health and numerous biopharmaceutical companies and disease foundations have teamed up on an unusual project to find and bring new medicines to patients faster. The Accelerating Medicines Partnership, announced Tuesday, will focus on the early part of drug research.
Researchers at Oregon State Univ. have discovered a genetic function that helps one of the most important “tumor suppressor” genes to do its job and prevent cancer. Finding ways to maintain or increase the effectiveness of this gene—called Grp1-associated scaffold protein, or Grasp—could offer an important new avenue for human cancer therapies, scientists said.
The Food and Drug Administration said Friday it is reviewing the safety of popular testosterone drugs for men in light of recent studies suggesting they can increase the risk of heart attack, stroke and death. A study suggested testosterone therapy could double the risk of those problems in men older than 65. Another study published in November found that the hormone increased the risk by 30%.
Cancer drugs that recruit antibodies from the body’s own immune system to help kill tumors have shown much promise in treating several types of cancer. However, after initial success, the tumors often return. A new study from Massachusetts Institute of Technology reveals a way to combat these recurrent tumors with a drug that makes them more vulnerable to the antibody treatment.
Drugmaker Merck & Co. is joining two dozen other pharmaceutical companies and contract laboratories in committing to not use chimpanzees for research. The growing trend could mean roughly 1,000 chimps in the U.S. used for research or warehoused for many years in laboratory cages could be "retired" to sanctuaries by around 2020.